3. TNBC Dose Expansion Cohort: Patients must have a diagnosis of histologically confirmed metastatic TNBC defined as negative for estrogen receptor, progesterone receptor and human epidermal growth factor 2 (HER2). Patients must have received either adjuvant or first line chemotherapy for metastatic disease.